Can AI remedy the growing pains of digital biomarker development?
AI implementation could be a useful tool to analyse generated data. Yet, regulatory approval hurdles are in sight.
By
AI implementation could be a useful tool to analyse generated data. Yet, regulatory approval hurdles are in sight.
ByThere are a variety of noninvasive NASH tests currently available and under investigation—but how can they be optimised?
ByDigital simulation could help break down healthcare barriers, but experts caution the clinical trials sector to go slow.
ByWomen tend to be harder to recruit for clinical trials due to socioeconomic factors. But decentralised study designs help ease…
ByDCT Adoption Tracker: Clinical Trials Arena reviews the burgeoning trend on remote monitoring and look into regulatory know-how needed to…
ByThe FDA has released new guidance on how to integrate patient engagement in medical device clinical studies. How might patient…
ByRoutine childhood immunisation programmes have been disrupted because of Covid-19 and their implementation should be prioritised.
ByPsilocybin showed positive signs as a potential treatment for neurological conditions, but safety concerns need to be addressed.
ByThank you for subscribing to Clinical Trials Arena